BioSpace News Archive

Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of two oral abstract presentations at the upcoming European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress being held virtually from June 6 to 8, 2020. The following virtual oral abstract presentations will be available starti

- I-Mab to initiate Phase 2 clinical trial in glioblastoma multiforme (GBM) in China - I-Mab and Genexine expand collaboration for development of TJ107/HyLeukin-7™

Boston Children’s Hospital’s Center on Media and Child Health (CMCH) today released the " Family Digital Wellness Guide ,” a free interactive handbook of essential evidence-based “Protips” for p

GetHealthy Network Hosts E-Commerce Supplement Stores with a Network of Over 1,000 Medical Practitioners Nationwide

Incyte announced that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 8:00 a.m. ET.

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that multiple case series and studies will be presented at the Annual European Congress of Rheumatology (EULAR 2020), being held virtually June 3 - 6, 2020. Several presentations of clinical trial data and in-practice cases will provide results on KRYSTEXXA

May 21, 2020, Switch Health Holdings Inc. is pleased to announce the launch of its first Mobile Rapid Testing Unit, designed to assist in the fight against COVID-19.

New features help clients safeguard care teams and cancer patients, proactively communicate, and ensure access to care - Patient monitoring system helps cancer patients minimize office visits, reducing the risk of exposure to COVID-19 - Remote monitoring of symptoms reduces unnecessary ER visits - Newly released questionnaire feature screens for COVID-19 symptoms

Primary endpoint achieved in global, randomized, Phase 3 study of omidubicel; Initiation of BLA submission planned for fourth quarter of 2020 — – Additional data from GDA-201 program expected in second half of 2020 – – $60 million follow-on offering expected to close today – – Company to host conference call at 8:30 a.m. ET today – BOSTON--( BUSINESS WIRE )-- Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company com

SutroVax, Inc., a next-generation vaccine company, today announced that it has changed its name to Vaxcyte, Inc. The new name more accurately reflects the Company’s mission to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. “We are committed to developing superior vaccines that provide broader protection than what is available c